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Background: Androgen receptor (AR) regulation of transcription is required for male genital development in utero.
Results:AnARNH2-terminal mutation caused partial androgen insensitivity by creating a phosphorylation site and disrupting
coregulator effects of melanoma antigen-A11 (MAGE-11).
Conclusion:MAGE-11 is an obligatory coregulator during human male fetal genital development.
Significance: AR signaling during the critical period of male fetal genital development requires MAGE-11.
Naturally occurring germ line mutations in the X-linked
human androgen receptor (AR) gene cause incomplete mascu-
linization of the external genitalia by disrupting AR function in
maleswith androgen insensitivity syndrome.Almost all ARmis-
sensemutations that cause androgen insensitivity syndrome are
located in the highly structured DNA and ligand binding
domains. In this reportwe investigate the functional defect asso-
ciatedwith anAR exon 1missensemutation, R405S, that caused
partial androgen insensitivity. The 46,XX heterozygous mater-
nal carrier had a wild-type Arg-405 CGC allele but transmitted
an AGC mutant allele coding for Ser-405. At birth, the 46,XY
proband had a bifid scrotum, hypospadias, andmicropenis con-
sistent with clinical stage 3 partial androgen insensitivity.
Androgen-dependent transcriptional activity of AR-R405S
expressed inCV1 cells was less thanwild-typeARand refractory
in androgen-dependentARNH2- and carboxyl interaction tran-
scription assays that depend on the coregulator effects of mela-
noma antigen-A11. This mutation created a Ser-405 phosphor-
ylation site evident by the gel migration of an AR-R405S
NH2-terminal fragment as a double band that converted to the
wild-type single band after treatment with -phosphatase. Det-
rimental effects of the R405Smutationwere related to the prox-
imity of the ARWXXLFmotif 433WHTLF437 required for mela-
noma antigen-A11 and p300 to stimulate transcriptional
activity associated with the AR NH2- and carboxyl-terminal
interaction. We conclude that the coregulator effects of mela-
noma antigen-A11 on the AR NH2- and carboxyl-terminal
interaction amplify the androgen-dependent transcriptional
response to p300 required for normal humanmale sex develop-
ment in utero.
The androgen receptor (AR)2 is a ligand-dependent tran-
scription factor thatmediates humanmale genital development
in utero and growth at puberty. AR regulates androgen-depen-
dent gene transcription in response to high affinity binding of
testosterone or dihydrotestosterone (DHT). In utero human
male external genital development depends on DHT, the most
potent naturally occurring androgen that stabilizes the andro-
gen-dependent ARNH2- and carboxyl-terminal (N/C) interac-
tion (1). Naturally occurring single amino acid missense muta-
tions in the AR gene at Xq11–12 on the human X chromosome
cause partial or complete androgen insensitivity syndrome
(AIS), a disorder of sex development that results in incomplete
masculinization of the 46,XY genetic male fetus. Incomplete
development of external genitalia of 46,XY genetic males
caused by AR gene mutations demonstrates the functional
requirement for androgen-dependent AR signaling (2). Natu-
rally occurring genemutations in the 5-reductase enzyme that
converts testosterone to DHT can cause a phenotype similar to
AIS at birth and demonstrate the requirement for optimal
androgen signaling for normal human male genital develop-
ment in utero (3).
The prevalence of AR gene mutations that cause AIS in the
general population is0.01%. The primary diagnostic criterion
for AIS is the identification of an AR gene mutation (4). CpG
dinucleotides are the most prevalent mutation sites through
methylation and deamination of cytidine in genomic DNA (5,
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6). Most of the 200 unique naturally occurring AR gene mis-
sense mutations cause AIS by disrupting function in the highly
structured DNA and ligand binding domains (7). However, the
large AR NH2-terminal region coded by exon 1 is also required
for AR activity (8). AR genemissensemutations in theARNH2-
terminal region would be expected to occur with a frequency
similar to theDNAand ligandbinding domains.However,most
of the naturally occurring mutations in the NH2-terminal
region that cause AIS introduce premature termination codons
that interrupt transcription and cause rapid degradation of the
ARmessenger RNA or expression of an inactive truncated pro-
tein. A notable exception is amissensemutation at the ARNH2
terminus that interfered with translation initiation (9). The rel-
ative lack of reported missense mutations in the AR NH2-ter-
minal transactivation domain that cause AIS can best be
explained by the unstructured nature of this region (10). Inher-
ent structural flexibility within the ARNH2-terminal transacti-
vation domain may be sufficient to accommodate a missense
mutation that is undetected in the general population.
AR transcriptional activity depends on interactions with
coregulator proteins (11) and on the androgen-dependent
interdomain AR N/C interaction between the AR NH2-termi-
nal FXXLF motif and activation function 2 (AF2) in the ligand
binding domain (12, 13). The AR AF2 hydrophobic surface
flanked by charged residues also binds LXXLL motifs of p160
coactivators but with lower affinity than AF2 binds the AR
FXXLF motif or FXXLF motifs in other transcriptional regula-
tors (1, 14, 15). The AR N/C interaction is modulated by pri-
mate-specific melanoma antigen-A11 (MAGE-11) that binds
the AR FXXLF motif and functions synergistically with the AR
N/C interaction, coregulators, and transcription factors (16–
20). An AR NH2-terminal WXXLF motif contributes to the AR
N/C interaction through mechanisms not well understood (21,
22). Disruption of the AR N/C interaction by mutating the AR
NH2-terminal FXXLF motif inhibits AR transcriptional activa-
tion of androgen-responsive reporter genes (23). Although no
naturally occurringmutation has been reported in theARNH2-
terminal FXXLFmotif, the ARN/C interaction is thought to be
important for AR transcriptional activity in vivo. Naturally
occurring mutations in the AF2 site that disrupt the AR N/C
interaction and cause AIS but retain high-affinity androgen
binding support a requirement for the N/C interaction in AR
function (14, 24–30).
In this report, we provide evidence that the functional defect
associated with naturally occurring ARNH2-terminalmissense
mutation AR-R405S caused clinical stage 3 partial AIS by inter-
ference with the stimulatory effects of the AR coregulator
MAGE-11. The Arg-405-to-Ser-405 mutation with amino acid
numbering on the basis of human AR reported by Lubahn et al.
(31), created a new phosphorylation site and interferedwith the
effects of MAGE-11 on androgen-dependent transcriptional
activity associated with the AR N/C interaction. The results
show that the AR NH2-terminal 433WHTLF437 WXXLF motif
that lies in close proximity to the AR R405S mutation is
required for transcriptional activation associated with the
coregulator effects of MAGE-11 and p300.
EXPERIMENTAL PROCEDURES
Clinical Analysis—Studies were performed with informed
consent and approval from the University of North Carolina at
Chapel Hill and WakeMed Health and Hospitals institutional
review boards. Genomic DNA sequencing of the full AR coding
region performed at the Baylor College of Medicine revealed a
single CGC3 AGCmutation in exon 1 of the newborn 46,XY
Caucasian proband. The AR exon 1 CGC3 AGC mutation in
the proband andmotherwas confirmedby sequencing genomic
DNA isolated from blood leukocytes using the QIAamp Blood
Maxi kit spin protocol according to themanufacturer (Qiagen).
Genomic DNA (25 ng) was PCR-amplified using 2.5 units
GoTaq Flexi DNA polymerase (Promega) in 50-l reactions
containing Taq Flexi buffer, 0.2 mM deoxynucleotide triphos-
phates (Amersham Biosciences), 2.5 mM MgCl2, Q solution
(Qiagen), 0.2 M human AR primer 5-GGGTGTGGAG-
GCGTTGGAGC-3 (forward) and 0.2 M primer 5-TGAC-
CCAGAACCGGGTCCCG-3 (reverse). PCR amplification
was performed at 95 °C for 5 min followed by 20 cycles of 95 °C
for 1 min, 55 °C for 1 min, 72 °C for 45 s, and then 72 °C for 7
min. The DNA sequence was determined for a 532-bp exon 1
fragment that codes for AR amino acid residues 248–424.
Amino acid repeats in AR of the proband were 21 glutamine
and 17 glycine residues.
DNA Vectors—pSG5-MAGE codes for full-length human
MAGE-A11 (MAGE-11) (16), and pSG5-HA-p300 codes for
human influenza hemagglutinin-tagged p300 (18). pCMV-AR
coding for full-length human AR (31) and pCMV-AR-1–660
for the AR NH2-terminal and DNA binding domains (8) were
mutated to R405S, R405A or Y406F by QuikChange site-di-
rected mutagenesis (Stratagene) using PfuTurbo DNA polym-
erase (Agilent). pCMV-AR-507–919 codes for the human AR
DNA and ligand binding domains (8). pCMV-AR-1–503 codes
for the AR NH2-terminal domain (12), pCMV-AR-1–503-
L26A,F27A for the AR FXXLF motif mutant, and pCMV-AR-
1–503-W433A/L436A/F437A (AR-1–503-AXXAA) for the
WXXLFmotifmutant (21). pCMV5-AR-1–503-R405Swas cre-
ated by digesting pCMV5-AR-R405S with KpnI and XbaI fol-
lowed by blunt end ligation. pCMV5-AR-1–503-R405A was
created by digesting pNLVP16-AR-1–660-R405A with BsmI
and BstEII and cloning the insert into pCMV-AR-1–503.
pCMV-AR-1–660406–409 was created by double PCR
mutagenesis and cloning the insert into BsmI and BstEII sites in
AR. The same fragment was subcloned to make pCMV-AR-1–
503406–409. GAL-AR-1–449 was created by PCR amplify-
ing pCMV-AR and cloning the insert into NdeI and XhoI sites
of pGALO (32, 33) and the R405S mutant by QuikChange
mutagenesis. VP-AR-507–919 was created by inserting a PCR-
amplified pCMV-AR fragment into the MluI and XbaI sites of
pVP16 (Clontech). GAL-AR-400–449 and the AXXAA muta-
tion of the WXXLF motif were created by subcloning PCR-
amplified AR fragments into the EcoRI and BamHI sites of
GALO and the R405S mutant by QuikChange mutagenesis.
GAL-AR-1–422 was created by digesting GAL-AR with BstEII
andXbaI and self- ligation. Luciferase reporter vectors included
human prostate-specific antigen enhancer luciferase (PSA-
Enh-Luc) (18, 34), prostate stem cell antigen androgen
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response element-luciferase with four multimerized androgen
response element-1 (PSCA-ARE-Luc) (35), p21-Luc (36) and
5XGAL4Luc3 (18, 37). Integrity of all PCR-amplified regions
was verified by DNA sequencing.
Transcription Assays—Monkey kidney CV-1 cells (4  105/6
cm dish) were transfected with wild-type and mutant expres-
sion and luciferase reporter vector DNA using calcium phos-
phate precipitation. Cells were treated twice for consecutive
24-h periods with and without DHT in serum-free phenol red-
free medium prior to assaying luciferase activity (19, 21).
Human cervical cancer HeLa cells (5  104/well in 12-well
plates) were transfected with expression and reporter vector
DNA using FuGENE 6 (Roche). Inhibition of endogenous
MAGE-11 expression in HeLa cells (1.2  105 cells/well in
6-well plates) was performed without antibiotics using Lipo-
fectamine 2000 (Invitrogen) with and without 2 nM nonspecific
siRNA-3 or MAGE-11 siRNA-2 and siRNA-3 (Dharmacon)
(18). Luciferase activity was measured after 24 h in serum-free
phenol red-free medium in the absence and presence of testos-
terone or DHT (1, 19) using an automated Lumistar Galaxy
luminometer (BMG Labtech). Data shown (mean  S.E.) are
representative of at least three independent experiments.
Immunoblot Analysis—Monkey kidney COS-1 cells (2 
106/10-cm dish) were transfected with 5–10 g of plasmid
DNA using DEAE dextran (1, 38). HeLa cells (7.5  105/10-cm
dish) were transfected with 2 g DNA using FuGENE 6
(Roche). Cells were transferred to serum-free media with and
without 1 M MG132 proteasome inhibitor (Sigma) or DHT,
incubated for 24 h, and harvested in 0.1–0.2 ml of lysis buffer
containing 1% Triton X-100, 1% sodium deoxycholate, 0.1%
SDS, 0.15 M NaCl, 2 mM EDTA, 50 mM NaF, 2 mM sodium
vanadate, 50 mM Tris-HCl (pH 7.6), 1 mM phenylmethylsulfo-
nyl fluoride, 1 mM dithiothreitol, and complete protease inhib-
itor mixture (Roche). To verify phosphorylation at the R405S
mutation site, 2 l -phosphatase (New England Biolabs,
400,000 units/ml) was added to 40 g of cell extract protein
prepared in lysis buffer as above, except without NaF, sodium
vanadate, EDTA, or deoxycholate, and incubated for 1 h at 4 °C.
Extracts were analyzed on transblots of acrylamide gels con-
taining SDS using 1 g/ml rabbit polyclonal AR32 antipeptide
antibody (39) or a 1:500 dilution of rabbit anti-GAL4 DNA
binding domain antibody sc577 (Santa Cruz Biotechnology).
Gels were calibrated using an EZ-Run prestained Rec protein
ladder (Fisher Bioreagents).
RESULTS
Clinical Phenotype—The 46,XY Caucasian male proband
was born premature at 25 weeks of gestational age with a bifid
scrotum, hypospadias, micropenis, intra-abdominal testes, and
absence of a uterus. Serum hormone levels (Esoterix, Inc.)
obtained on the first day of life were 3252 ng/dL 17OH-preg-
nenolone (normal range 375–3559 ng/dL), 868 ng/dL 17OH-
progesterone (124–841 ng/dL), 998 ng/dL progesterone (18–
640 ng/dL), 25 ng/dL deoxycorticosterone (20–105 ng/dL), 226
ng/dL 11-desoxycortisol (18–640 ng/dL), 166 ng/dL andro-
stenedione (63–935 ng/dL), 1.4 g/dL cortisol (1.0–11 g/dL),
1030 ng/dL dehydroepiandrosterone (236–3640 ng/dL), 502
ng/dL testosterone (59–125 ng/dL), 31 ng/dL DHT (10–53
ng/dL) and testosterone to DHT ratio of 16.2 ( 18).
The incompletely masculinized external phenotype and ele-
vated serum testosterone of the proband were consistent with
clinical stage 3 partial AIS (7). GenomicDNA sequencing of the
entire AR coding region indicated a single CGC3AGCmuta-
tion in exon 1 of the AR gene (Fig. 1, right panel). AR NH2-
terminal 21 glutamine and 17 glycine repeat lengths were in the
normal range. Assays of androgen binding affinity and capacity
of genital skin fibroblasts were not performed because the
ligand binding domain sequence was wild-type. Although there
was no family history of AIS, the maternal genomic DNA
sequence in the region of the proband mutation indicated a
heterozygous carrier with CGCwild-type allele coding for Arg-
405 and AGC mutant allele coding for Ser-405 (Fig. 1, left
panel), consistent with the X-linked inheritance pattern of AIS.
The 46,XXmaternal carrier had a normal distribution of pubic
and axillary hair that may be explained by the random inactiva-
tion of one X chromosome and the partial AIS defect. The pro-
band inherited the AGC mutant allele coding for Ser-405.
Clinical classification of stage 3 AIS and male gender assign-
ment indicated retention of partial AR transcriptional activity.
This was confirmed by a neonatal penile growth response to
androgen therapy that preceded reconstructive surgery.
The R405S mutation is positioned in the region of AR NH2-
terminal activation function 1 and 27 residues from NH2-ter-
minal WXXLF motif sequence 433WHTLF437 (Fig. 2) impli-
cated in the androgen-dependent AR N/C interaction and
transcriptional activity (13, 21–23). Expression studies using
wild-type andmutant AR and select AR fragments (Fig. 2) were
performed to determine the mechanism by which the R405S
mutation disrupted AR transcriptional activity and caused par-
tial AIS.
Transcriptional Activity of AR-R405S—Transcriptional con-
sequences of the AR R405Smutation were investigated initially
by determining full-length AR activation of androgen-respon-
FIGURE 1. Genomic DNA sequence from maternal heterozygous carrier
and 46,XY proband with clinical stage 3 partial AIS. Genomic DNA was
isolated from blood leukocytes from the mother and newborn 46,XY proband
with incomplete masculinization. DNA sequencing profiles indicate WT CGC
allele coding for AR Arg-405 in the mother and AGC mutant allele coding for
Ser-405 in mother and baby. The full AR coding sequence determined from
baby genomic DNA revealed a single AR exon 1 CGC3AGC mutation coding
for the AR R405S mutation. Thymidine nucleotide (T) 1210 is numbered rela-
tive to the ATG translation start site.
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sive reporter genes. There was similar expression of human AR
and AR-R405S (Fig. 3A). The increase in band intensity with
DHT for wild-type and mutant AR suggested that the R405S
mutation does not interfere with the stabilizing effect of the
androgen-dependent N/C interaction between the AR NH2-
terminal FXXLF motif and AF2 in the ligand binding domain
(21). Transcription assays using androgen-responsive reporter
genes demonstrated overall reduced activity of AR-R405S com-
pared with wild-type AR. AR-R405S transactivation of the PSA
enhancer region (PSA-Enh-Luc) in CV1 cells was less than
wild-type using 25 ng AR vector DNA (Fig. 3B). However, this
difference was not seen with 50 ng of AR DNA (Fig. 3B).
AR-R405S transcriptional activitywas similar to or greater than
wild-type AR in HeLa cells at increasing concentrations of tes-
tosterone or DHT with the PSA-Enh-Luc (Fig. 3C), prostate
stem cell antigen androgen response element-Luc (Fig. 3D), or
the p21-Luc reporter gene (Fig. 3E). The results indicated that
the inhibitory effects of the AR R405S mutation were discern-
able in transcription assays performed inCV1 cells utilizing low
amounts of full-length AR and androgen.
Inhibitory effects of the R405S mutation were evaluated fur-
ther with respect to constitutive activity of AR NH2-terminal
and DNA binding domain fragments that lack the ligand bind-
ing domain. Expression levels of wild-type AR-1–660 and the
corresponding R405S mutant were similar, and AR-1–660-
R405S migrated faster than the wild-type fragment (Fig. 4A).
Increasing amounts of AR-1–660 or AR-1–660-R405S
increased transactivation of PSA-Enh-Luc to a similar extent in
HeLa cells (Fig. 4B). Expression ofMAGE-11 increased the con-
stitutive activity of AR-1–660 and the R405S mutant (Fig. 4C).
The R405S mutation did not diminish the synergistic increase
in AR-1–660 constitutive activity by MAGE-11 and p300 (Fig.
4D). The R405S mutation also did not interfere with AR con-
stitutive activity by influencing phosphorylation at Tyr-406 in a
predicted Janus kinase 2 406YXXL409 consensus site (40).
AR-1–660-Y406F and 406–409 expression (Fig. 4A) and
constitutive activity (Fig. 4B) were like the wild type, and the
MAGE-11-dependent increase in AR-1–660406–409 activ-
ity was similar to AR-1–660 (Fig. 4C).
The results suggest that the AR R405S mutation does not
interfere with transcriptional activity emanating directly from
the AR NH2-terminal transactivation region, nor did it influ-
ence phosphorylation at a potential Janus kinase 2 site. How-
ever, the results did not rule out interference of AR transcrip-
tional activity associated with the AR N/C interaction or
phosphorylation of the mutant Ser-405.
Requirement for the ARWXXLFMotif in AR N/C Interaction
Transactivation byMAGE-11 and p300—TheARFXXLFmotif
binding to AF2 is the principal interaction of the androgen-de-
pendent AR N/C interaction, whereas the AR NH2-terminal
WXXLF motif contributes through a mechanism that is not
well understood (13). Although androgen-dependent stabiliza-
tion of AR-R405S indicated an AR N/C interaction like wild-
type AR (Fig. 3A), proximity of the R405S mutation 27 amino
acid residues from the WXXLF motif (Fig. 2) raised the possi-
bility that the R405S mutation might interfere with WXXLF
motif binding to AF2 in the AR ligand binding domain or with
transcriptional activity associated with the ARN/C interaction.
To test the effect of theR405Smutation onARWXXLFmotif
binding to the AF2 region, wild-type GAL-AR-400–449 and
mutants (Figs. 2 and 5A) were expressed in the absence and
presence ofDHTwithVP-AR-507–919, anARDNAand ligand
binding domain fragment. It was noteworthy that GAL-AR-
400–449-R405S had additional up-shifted bands not seen with
GAL-AR-400–449 or theAXXAAmutant of theWXXLFmotif
(Fig. 5A, lanes 4–6). However, the similar androgen-dependent
transcriptional activity resulting from GAL-AR-400–449 or
GAL-AR-400–449-R405S interaction with VP-AR-507–919
(Fig. 5B) suggested that the R405S mutation does not interfere
with WXXLF motif binding to AF2. Decreased transcriptional
activity of GAL-AR-400–449-AXXAA expressed with VP-AR-
507–919 demonstrated dependence on theWXXLF motif (Fig.
5B).
Transcriptional activity associated with the AR NH2-termi-
nal WXXLF motif region was examined in AR NH2-terminal
fragments outside the context of the AR N/C interaction. The
similar increase inGAL-AR-400–449 and R405Smutant activ-
ity by MAGE-11 or p300 was not seen with the GAL-AR-400–
449-AXXAA WXXLF motif mutant (Fig. 5C). MAGE-11
increased activity of GAL-AR-1–449 (Fig. 5A, lane 2), which
contains both AR FXXLF and WXXLF motif regions, to a
greater extent than it increased activity of GAL-AR-1–422 (A,
lane 3), which lacks theWXXLFmotif (D). However, activation
by p300 was similar for GAL-AR-1–449 and GAL-AR-1–422,
most likely because in the absence of the WXXLF motif, p300
interacts with other regions of the AR NH2-terminal domain.
The results suggest that the ARNH2-terminalWXXLFmotif
facilitates transcriptional activation by MAGE-11 and p300.
The R405S mutation altered electrophoretic mobility of the
AR-400–449 fragment but did not inhibit the N/C interaction
mediated by the AR WXXLF motif. The principal function of
the WXXLF motif appeared to be transcriptional activation by
MAGE-11 and p300.
Phosphorylation ofMutant AR Ser-405—The altered electro-
phoretic migration of AR-1–660 (Fig. 4A) and GAL-AR-400–
449 (Fig. 5A) by the R405S mutation suggested a change in
posttranslational modification that involves phosphorylation.
Phosphorylation of mutant AR Ser-405 was suggested by the
double bandmigration of GAL-AR-400–449-R405S compared
with single bands for GAL-AR-400–449 and GAL-AR-400–
FIGURE 2. Schematic diagram of full-length human AR and fragments.
Full-length human AR contains 919 amino acid residues on the basis of num-
bering of Lubahn et al. (31). The AR R405S mutation (wild-type Arg-405, R
underlined) is located 27 residues from WXXLF motif sequence 433WHTLF437
flanking AF1 in the NH2-terminal region. Wild-type and mutant GAL-AR-400 –
449 fusion proteins, AR-1– 660 NH2-terminal and DNA binding domain (DBD)
fragment, AR-1–503 NH2-terminal fragment, and AR-507–919 DBD and
ligand binding domain (LBD) fragment that contains AF2 were expressed to
delineate inhibitory effects of the AR R405S mutation.
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449-AXXAA (Fig. 6A). Phosphorylation atARSer-405was con-
firmed when the GAL-AR-400–449-R405S double band was
rendered a single band like GAL-AR-400–449 after treatment
with -phosphatase (Fig. 6B). A longer exposure of a transblot
of GAL-AR-400–449-R405S revealed an additional up-shifted
band (also evident in Fig. 5A) that was eliminated by -phos-
phatase (Fig. 6C). Treatment of cells with 10 ng/ml EGF or 10%
serum did not significantly alter GAL-AR-400–449-R405S
phosphorylation on the basis of intensity of the up-shifted
bands (data not shown). Gel migration of AR-1–503 and the
R405S andAXXAAmutants was also influenced by -phospha-
tase treatment (Fig. 6D) with varying intensities of faster
migrating bands (Figs. 4A, 5A, and 6D), suggesting limited
proteolysis.
The results suggest that loss of function by the AR R405S
mutation was associated with phosphorylation of Ser-405. The
FIGURE 3. Transcriptional activity of AR-R405S. A, pCMV5 empty vector (-), pCMV-AR full-length WT, and R405S mutant (5 g) were expressed in COS-1 cells
in the absence and presence of 10 nM DHT. Cell extracts (40 g protein/lane) were probed on the transblot using AR32 antibody. B, pCMV-AR WT and R405S
mutant (25 and 50 ng) were expressed in CV-1 cells with 4 g PSA-Enh-Luc. Cells were incubated with and without increasing concentrations of DHT. C and D,
pCMV-AR WT and R405S mutant (10 ng) were expressed in HeLa cells with 0.25 g PSA-Enh-Luc (C) or 0.25 g PSCA-ARE-Luc (D). Cells were incubated with and
without increasing concentrations of testosterone (T) or DHT. E, pCMV-AR WT and R405S mutant (50 ng) were expressed in HeLa cells with 0.25 g p21-Luc.
Cells were incubated with and without 0.1 or 1 nM DHT. Luciferase activity is expressed as the mean  S.E. and is representative of at least three independent
experiments.
FIGURE 4. Effect of MAGE-11 and p300 on AR-1– 660 constitutive activity.
A, pCMV5 empty vector (-) or pCMV-AR-1– 660 WT, R405S, Y406F, and 406 –
409 (8 g DNA) were expressed in COS-1 cells. Cell extracts (50 g protein/
lane) were probed on a transblot using AR32 antibody. B, pCMV5 empty vec-
tor (50 ng) (-) or 25, 50, and 100 ng pCMV-AR-1– 660 WT coding for AR NH2-
terminal and DNA binding domains and R405S, Y406F, and 406 – 409
mutants were expressed in HeLa cells with 0.1 g of PSA-Enh-Luc. C, pCMV5
empty vector, pCMV-AR-1– 660 WT, R405S, and 406 – 409 (10 ng) were
expressed in HeLa cells with 0.1 g PSA-Enh-Luc and 10 or 25 ng pSG5 empty
vector (-) or pSG5-MAGE (M). D, pCMV5 empty vector (-), pCMV-AR-1– 660 WT,
and R405S mutant (10 ng) were expressed in CV1 cells with 2.5 g PSA-Enh-
Luc with and without 1.5 g of pSG5 empty vector (-), 0.5 g of pSG5-MAGE
(M), and/or 2 g of pSG5-HA-p300 (P). Luciferase activity is expressed as the
mean  S.E. and is representative of three independent experiments.
FIGURE 5. Effect of AR R405S and WXXLF motif mutations on AR activa-
tion by MAGE-11 and p300. A, GALO empty vector (-), GAL-AR-1– 449, GAL-
AR-1– 422, GAL-AR-400 – 449 WT, R405S, and the AXXAA mutation of the
WXXLF motif (10 g) were expressed in COS-1 cells, and 60 g of protein/lane
cell extracts were analyzed on an immunoblot using GAL4 DNA binding
domain antibody. B, GALO empty vector (-), GAL-AR-400 – 449 WT, R405S, and
the AXXAA mutation of the WXXLF motif (50 ng) were expressed in HeLa cells
with 0.1 g 5XGAL4Luc3 and 50 ng pNLVP16 empty vector (-) or VP-AR-507–
919. Cells were incubated in the absence and presence of 10 nM DHT. C and D,
GAL-AR-400 – 449 WT, R405S, or the AXXAA mutation of the WXXLF motif (50
ng) (C) and 10 ng of GALO empty vector (-), GAL-AR-1– 449, or GAL-AR-1– 422
(D) were expressed in HeLa cells with 0.1 g of 5XGAL4Luc3 with and without
100 ng of pSG5 empty vector (-), pSG5-MAGE (M), or pSG5-HA-p300 (P). Lucif-
erase activity is expressed as the mean  S.E. and is representative of three
independent experiments.
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AR R405S mutation was also associated with additional phos-
phorylation events in the AR NH2-terminal region.
AR R405S Mutation Interferes with MAGE-11 Activation of
AR N/C Interaction-dependent Transcriptional Activity—An
inhibitory effect of the R405S mutation on AR activity at 0.01
nM DHT was not seen with the neutral AR-R405A mutant
despite similar expression levels (Fig. 7A), supporting the neg-
ative influence of phosphorylation at Ser-405 on AR transcrip-
tional activity. A detrimental effect of the R405S mutation was
also seen at 1–10 pM DHT when MAGE-11 was expressed in
CV1 cells (Fig. 7B) that have low endogenous levels of
MAGE-11 (19, 41). To test for an effect on the AR N/C inter-
action, wild-type AR-1–503 and R405S, FXXLF, and WXXLF
motif mutants that migrated as multiple bands (Fig. 7C) were
expressed with AR-507–919 in the absence and presence of 1
nM DHT, MAGE-11 and p300. Weak androgen-dependent
transcriptional activity from the intermolecular N/C interac-
tion between AR-1–503 and AR-507–919 increased sharply
with the expression of MAGE-11 or p300 (Fig. 7D). However,
MAGE-11 did not increase transcriptional activitywhenAR-1–
503-R405S was expressed with AR-507–919, even though
activity increased with p300. Loss ofMAGE-11 or p300-depen-
dent activity when AR-1–503-L26A,F27A or AR-1–503-
AXXAA was expressed with AR-507–919 demonstrated
dependence of AR N/C interaction transcriptional activity on
the AR FXXLF and WXXLF motifs.
The results suggested thatMAGE-11 or p300 increases tran-
scriptional activity associated with the AR N/C interaction and
that the inhibitory effect of the AR R405Smutation on ARN/C
interaction activation by MAGE-11 can be overcome by
increasing the expression of p300. A requirement for endoge-
nous p300 in transcriptional activity associated with the andro-
gen-dependent AR N/C interaction was shown previously by
silencing p300 using siRNA (18). To further demonstrate a
requirement for endogenous MAGE-11, AR-1–503 was
expressed with AR-507–919 in HeLa cells that have higher lev-
els of MAGE-11 (19, 41). MAGE-11 siRNA-2, which inhibits
MAGE-11 expression in HeLa cells (18, 20), inhibited tran-
scriptional activity associated with the AR N/C interaction rel-
ative to nonspecific siRNA orMAGE-11 siRNA-3 (Fig. 7E) that
was less effective in inhibiting MAGE-11 expression (18, 20).
Inhibition of AR-R405S transcriptional activity associated with
the N/C interaction by knockdown of MAGE-11 suggested
residual activation of the mutant by MAGE-11.
Interference of AR transcriptional activity associated with
theN/C interaction by theARR405Smutationwas investigated
further in dose response studies by expressing increasing
amounts of wild-type or mutant AR-1–503 (Fig. 8A) with
AR-507–919. Androgen-dependent transcriptional activity
associated with the intermolecular AR N/C interaction was
similar when 10 ng of AR-1–503 or AR-1–503-R405S was
expressed with AR-507–919 (Fig. 8, B–D). This agreed with
results in Fig. 3A that the R405S mutation does not disrupt
androgen-dependent AR stabilization by the N/C interaction.
However, the dose-dependent increase in transcriptional activ-
ity seen with 25 or 50 ng of wild-type AR-1–503 did not occur
with the same amounts ofAR-1–503-R405S (Fig. 8B). This con-
trasted the dose-dependent increase in ARN/C interaction-de-
pendent transcriptional activity that results from AR-1–503-
Y406F or AR-1–503406–919 interaction with AR-507–919
(Fig. 8C). Like AR-1–503-R405S, the dose-dependent increase
in activity associated with the AR N/C interaction was lost
when the AR-1–503-AXXAAmutant of theWXXLFmotif was
expressed with AR-507–919 (Fig. 8, D and E). However, there
was no inhibition by AR-1–503-R405A (E).
Overall, the results suggest that MAGE-11 facilitates tran-
scriptional activity associated with the ARN/C interaction that
depends on the ARWXXLF motif and activation by p300 (Fig.
9). Inhibition of the MAGE-11-dependent increase in AR N/C
interaction transcriptional activity by the AR R405S mutation
was rescued by increasing the expression of p300. The data
suggest that the AR R405S mutation caused partial AIS by cre-
ating a new phosphorylation site that interfered with the ability
of MAGE-11 to increase AR N/C interaction-dependent tran-
scriptional activation by p300.
DISCUSSION
Androgen Sensitivity of Normal Human Male Sex De-
velopment—Human male genital development in utero
depends on AR signaling in response to DHT, the most potent
naturally occurring androgen. The essential role of DHT in
development of the human fetal male external phenotype is
evident by the lack of genital development in newborns with
5-reductase deficiency that results in insufficient conversion
of testosterone to DHT (3, 42). The greater potency of DHT,
which binds AR with an equilibrium binding affinity similar to
testosterone (43), results from the nonpolar properties of DHT
that better stabilize the androgen-dependent AR N/C interac-
tion and slow androgen dissociation (1). This suggests that the
AR N/C interaction is critical for normal human male genital
development. However, no naturally occurring mutation in the
AR NH2-terminal FXXLF motif that mediates the AR N/C
interaction has been reported. The physiological significance of
the AR N/C interaction in androgen signaling has been indi-
cated by its strict dependence on agonists with strong in vivo
FIGURE 6. The AR R405S mutation creates a new phosphorylation site. A,
GAL-AR-400 – 449 WT, 433AXXAA437 (AX), and R405S mutants (10 g) were
expressed in COS-1 cells. The day before harvest, cells were incubated over-
night with 1 M MG132 proteasome inhibitor. Cell extracts (22 g of protein/
lane) were probed on the immunoblot using GAL4 DNA binding domain anti-
body. B, GALO empty vector (-), GAL-AR-400 – 449 WT, and R405S mutant (10
g) were expressed in COS-1 cells. Cell extracts (40 g of protein) were pre-
pared in lysis buffer without phosphatase inhibitors and incubated at 4 °C for
1 h with and without -phosphatase as described under “Experimental Pro-
cedures.” The transblot was probed with the GAL4 antibody. C, longer expo-
sure of a parallel blot prepared as described in B. D, pCMV5 empty vector (-),
pCMV-AR-1–503 WT, R405S, and the AXXAA mutations of the WXXLF motif (5
g) were expressed in COS-1 cells. Cell extracts (30 g of protein) prepared in
lysis buffer without phosphatase inhibitors were treated for 1 h at 4 °C with
and without -phosphatase and analyzed on a transblot using AR32
antibody.
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androgen activity (30, 44–47) and inhibition by classical AR
antagonists (12, 30). Synthetic androgens with partial agonist
activity have not induced the ARN/C interaction (44, 48). Nat-
urally occurring mutations in the AF2 site of the AR ligand
binding domain that retain high affinity androgen binding can
cause partial AIS by disrupting the AR N/C interaction (14,
24–30). However, the AR AF2 site also interacts with FXXLF
motifs of coregulators and LXXLL motifs of p160 coactivators.
In this report, we determined the mechanism by which the
naturally occurring AR NH2-terminal germ line mutation
R405S caused clinical stage 3 partial AIS in a 46,XY genetic
male born with a bifid scrotum, hypospadias, micropenis, and
FIGURE 7. AR R405S mutation inhibits the MAGE-11-dependent increase in AR N/C interaction-dependent transcriptional activity. A, pCMV-hAR WT
and R405S, R405A, and the AXXAA mutation of the AR WXXLF motif (25 ng) were expressed in CV1 cells with 2.5 g PSA-Enh-Luc in the absence and presence
of 0.01 nM DHT. Inset, pCMV5 empty vector (-) (5 g) and 5 g of pCMV-hAR WT, R405S, R405A, and the AXXAA mutation of the AR WXXLF motif were expressed
in COS cells. Cell extracts (20 g of protein/lane) were analyzed on the transblot using AR32 antibody. B, full-length pCMV-AR WT and the R405S mutant (25 ng)
were expressed in CV1 cells with 4 g of PSA-Enh-Luc and 0.5 g of pSG5 empty vector (-) or pSG5-MAGE. Cells were incubated with and without 1 and 10 pM
DHT. C, pCMV5 empty vector (-), pCMV-AR-1–503 WT, R405S, the AXXAA mutation of 433WHTLF437 (AX), and the L26A,F27A mutation of 23FQNLF27 (LFAA) (5 g)
were expressed in COS-1 cells. Cell extracts (10 g of protein/lane) were probed on the transblot using AR32 antibody. D, pCMV-AR-1–503 WT (0.3 g) and 0.3
g of pCMV-AR-1–503-R405S, AXXAA, or LFAA mutants were expressed in CV1 cells with 0.1 g of pCMV-AR-507–919 and 2.5 g of PSA-Enh-Luc with and
without 0.3 g of pSG5 empty vector (-), 0.3 g of pSG5-MAGE (M), or 1.5 g of pSG5-HA-p300 (P). Cells were incubated with and without 1 nM DHT. E,
pCMV-AR-507–919 (50 ng) was expressed in HeLa cells using Lipofectamine 2000 with 0.1 g of PSA-Enh-Luc and 50 ng of pCMV-AR-1–503 or R405S mutant
and 2 nM nonspecific (NS) siRNA, MAGE siRNA-2 (MAG2), or siRNA-3 (MAG3). Cells were incubated with and without 1 nM DHT, and luciferase activity was
measured.
FIGURE 8. Loss of AR N/C interaction-dependent transcriptional amplification by the AR R405S mutation. A, pCMV5 empty vector (-), pCMV-AR-1–503 WT,
R405S, the AXXAA mutation of the WXXLF motif (AX), R405A, Y406F, and 406 – 409 (5 g) were expressed in COS-1 cells. Cell extracts (10 g of protein/lane)
were analyzed on the transblot using AR32 antibody. B, pCMV-AR-507–919 (50 ng) was expressed in HeLa cells with 0.1 g of PSA-Enh-Luc and 25 ng of pCMV5
empty vector (-) or 10, 25, and 50 ng of pCMV-AR-1–503 WT or R405S mutant. C, pCMV-AR-507–919 (50 ng) was expressed in HeLa cells with 0.1 g of
PSA-Enh-Luc and 50 ng pCMV5 empty vector (-) or 10 and 50 ng of pCMV-AR-1–503 WT, R405S, Y406F, or 406 – 409 mutant. D, pCMV-AR-507–919 (50 ng) was
expressed in HeLa cells with 0.1 g of PSA-Enh-Luc and 50 ng of pCMV5 empty vector (-) or 10 and 50 ng of pCMV-AR-1–503 WT, R405S, AXXAA, or Y406F
mutant. E, pCMV-AR-507–919 (50 ng) was expressed in HeLa cells with 0.1 g of PSA-Enh-Luc and 50 ng of empty vector (-) or 50 ng of pCMV-AR-1–503 WT,
R405S, R405A, or AXXAA mutant. B–E, cells were incubated with and without 1 nM DHT, and luciferase activity was measured.
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intra-abdominal testes. The data suggest that the AR R405S
mutation interferes with the ability of MAGE-11, a primate-
specific AR coregulator, to increase androgen-dependent tran-
scriptional activity associatedwith theARN/C interaction (Fig.
9). The coregulator function ofMAGE-11 helps to recruit p300
through theARNH2-terminalWXXLFmotif during the critical
androgen-sensitive period of human male sex development in
utero.
Phosphorylation in the AR NH2-terminal Transactivation
Domain—Approximately 20 different naturally occurring AR
NH2-terminal missense mutations have been reported to cause
mild or partial AIS, compared with over 200 unique mutations
in theARDNAand ligandbinding domains that cause partial or
complete AIS. The fewer disrupting missense mutations in the
AR NH2-terminal region likely results from the absence of
structure in this region that affords greater flexibility to accom-
modate mutations and retain function (49, 50). Similar to the
AR R405S mutation, a P390S mutation also caused stage 3 par-
tial AIS associated with micropenis at birth (51) and infertility
and impaired spermatogenesis later in life (52). Similar to
R405S, the P390S mutation did not inhibit full-length AR tran-
scriptional activity when assayed using reporter genes and was
postulated to alter effects of an unknown AR coactivator. The
ARR405Smutation (and possibly the neighboring P390Smuta-
tion) appears to cause partial AIS by interfering with the ability
of MAGE-11 to increase AR transcriptional activity associated
with the AR N/C interaction mediated by p300 and the AR
FXXLF and WXXLF motifs.
Both AR R405S and P390S missense mutations caused clin-
ical stage 3 AIS by introducing a serine residue and potential
new phosphorylation site. Phosphorylation is a common post-
translational event in the ARNH2-terminal region that impacts
function to different extents (53–56). Some of the known AR
NH2-terminal phosphorylation sites include Ser-81, 308, and
515 phosphorylated by cyclin-dependent kinases (53, 54,
57–62), Ser-282 and 293 phosphorylated by Aurora-A kinase
(63), Ser-94 (53, 54), and Ser-578 (61). None of the documented
AR NH2-terminal phosphorylation sites has been reported to
be a site of a naturally occurring mutation that caused AIS.
However, phosphorylation at mutant AR Ser-405 was demon-
strated by altered electrophoretic migration of an AR NH2-
terminal fragment that was eliminated by treatment with
-phosphatase. There was also evidence for additional phos-
phorylation events triggered by the R405S mutation, and the
more neutral R405Amutation was not inhibitory. The findings
suggest that detrimental effects of the R405S mutation on AR
transcriptional activity were exacerbated by phosphorylation.
However, it is not known to what extent phosphorylation of
mutant AR Ser-405 occurred during humanmale genital devel-
opment. Treatment of cells with EGF or serum did not alter
Ser-405 phosphorylation on the basis of intensity of up-shifted
bands.
Regulation of ARN/C Interaction-dependent Transcriptional
Activity by MAGE-11 and p300—The AR R405S mutation lies
in a short predicted -helical region 27 residues from AR
WXXLFmotif sequence 433WHTLF437 that functions in theAR
N/C interaction (13) (Fig. 9). TheWXXLFmotif has been linked
to AR transcriptional activity and is a site of somatic mutations
in prostate cancer, although the mechanisms by which the
WXXLFmotif increasesAR activitywere unclear (13, 21, 22, 64,
65). Absence of an inhibitory effect of the R405S mutation on
WXXLFmotif binding to AF2 and on androgen-dependent AR
stabilization suggested that the AR R405S mutation does not
interfere with the androgen-dependent AR N/C interaction.
Retention of full-length AR transcriptional activity indicated
that the R405S mutation does not disrupt the AR N/C interac-
tion as seen with mutations in the AR FXXLF motif (23). How-
ever, transcriptional consequences of the AR R405S mutation
were evident at low DHT concentrations and in androgen-de-
pendent AR N/C interaction assays that depended on
MAGE-11.
MAGE-11 and p300 appear to be critical players in AR tran-
scriptional activity associated with the human ARN/C interac-
tion. siRNA studies showed that endogenous p300 (18) and
MAGE-11 are required for AR N/C interaction-dependent
transcriptional activity. Expression of wild-type andmutant AR
NH2-terminal fragments with the AR carboxyl-terminal frag-
ment showed that the R405S mutation did not disrupt the AR
N/C interaction but inhibited the gain in transcriptional activ-
ity seenwith higher amounts of theARNH2-terminal fragment.
This suggests that the AR R405S mutation interferes with the
increase in transcriptional activity associated with the AR N/C
interaction that depends on MAGE-11, p300, and the AR
WXXLF motif. MAGE-11 binds the AR NH2-terminal FXXLF
motif that mediates the AR N/C interaction (16), interacts
directly with p300 (18), and appears to be an obligatory factor in
the AR transcriptional response to p300. The molecular basis
for impaired male sex development in the 46,XY proband with
the AR R405S mutation appears to be interference with the
ability of MAGE-11 to increase AR N/C interaction-associated
transcriptional activation by p300.
Most of the AR NH2-terminal region is involved in andro-
gen-dependent AR transcriptional activity (8). This includes an
activation region between human AR amino acid residues 360
and 528 that includes the WXXLF motif and site of the R405S
FIGURE 9. AR R405S mutation interferes with MAGE-11 activation of AR
N/C interaction-dependent transcriptional activity mediated by p300
and the AR FXXLF and WXXLF motifs. A schematic representation is shown
for the AR NH2-terminal FXXLF motif binding to AF2 in the ligand binding
domain (LBD) in the presence of DHT that results in the androgen-dependent
AR N/C interaction (dotted line) between monomers of the AR antiparallel
dimer. MAGE-11 binding to the same AR FXXLF motif modulates the AR N/C
interaction to increase AR transcriptional activity. The AR R405S mutation
caused clinical stage 3 partial androgen insensitivity syndrome by creating a
new phosphorylation site and disrupting the ability of MAGE-11 to expose
the WXXLF motif region for activation by p300. Maximal AR transactivation by
MAGE-11 and p300 through AF1 and the AR NH2-terminal FXXLF and WXXLF
motif regions appears to be required for human male genital development in
utero.
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mutation. This activation region was required for constitutive
activity of AR NH2-terminal and DNA binding domain frag-
ments that lack the ligand binding domain but did not appear to
be required for full-length AR activity (66). The AR N/C inter-
actionmay temporarilymask theWXXLFmotif transcriptional
activation surface that is exposed by MAGE-11 for enhanced
transcriptional effects by p300.
Dependence onMAGE-11 for complete humanmale genital
development in utero implicates a second X-linked gene as a
possible cause of partial AIS. Although the human AR gene is
located at Xq11–12 (2) and is wild-type in some cases of 46,XY
partialAIS, theMAGE-11 gene is located atXq28on the human
X chromosome.MAGE-11 is expressed in normal human fore-
skin fibroblasts and other reproductive tract tissues (16). An
X-linked MAGE-11 gene mutation might account for unex-
plained cases of incomplete X-linked 46,XYmale genital devel-
opment where expression of wild-type AR is normal. However,
naturally occurringmutations in theMAGE-11 gene have yet to
be investigated as a cause of partial AIS.
AR mediates androgen-dependent gene transcription in all
mammals, but MAGE-11 is expressed only in human and non-
human primates (19). This suggests that MAGE-11 is not an
obligatory coregulator of AR function but provides a primate-
specific gain in function that augments AR signaling. AR is
transcriptionally active when expressed in CV1 cells that
express low levels of MAGE-11 (19, 41) and increases with
increased expression of MAGE-11 (16). The functional impor-
tance ofMAGE-11 as a primate-specific AR coregulator is sup-
ported by coevolution of the AR NH2-terminal sequence with
MAGE-11 expression. MAGE-11 first appeared during the pri-
mate lineage in parallel with an AR NH2-terminal mutation
from Ala-33 in less evolved mammals to Val-33 in human and
nonhuman primates. Human AR Val-33 is required for the AR
23FQNLF27 FXXLFmotif region to interact withMAGE-11 and
for competitive inhibitory effects of the AR N/C interaction on
AF2 activity that are relieved by MAGE-11 binding the AR
FXXLFmotif (19). This gain in regulatory control of humanAR
transactivation by MAGE-11 appears to be critical for normal
human male genital development in utero.
Clinical Prognosis—Sexual differentiation of the humanmale
external genitalia begins at 8 to 9 weeks of gestation and is
completed at 18 weeks of gestation in response to testoster-
one from Leydig cells of the fetal testis stimulated by placental
human chorionic gonadotropin and later by fetal pituitary
luteinizing hormone (67–71). The requirement for in utero
conversion of testosterone to DHT and the coregulator effects
ofMAGE-11 suggest thatmaximalAR signaling is necessary for
normal humanmale fetal genital development. Androgen ther-
apy prior to surgical repair significantly extended penile length
of the newborn 46,XY proband with the AR R405S mutation
and clinical stage 3 partial AIS. Partial fetal resistance to andro-
gen that caused incompletemasculinization at birth in this clin-
ical case may allow virilization in response to the pubertal rise
in testosterone, with possibly near normal male genital growth
and function. If virilization is unsatisfactory at puberty, the
patient will likely respond to androgen therapy that increases
circulating testosterone and DHT.
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